Edition:
India

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

7.40USD
1:30am IST
Change (% chg)

$0.22 (+3.06%)
Prev Close
$7.18
Open
$7.27
Day's High
$7.44
Day's Low
$7.05
Volume
464,865
Avg. Vol
222,699
52-wk High
$15.43
52-wk Low
$3.60

Gluck, Frederick 

Mr. Frederick W. Gluck serves as Independent Director of the Company. He has served as a member of our Board since September 2010 and was a member of the board of directors of CytomX Therapeutics, LLC until September 2010. Mr. Gluck previously served as a member of the board of directors of Amgen, Inc. from February 1998 to October 2011. He has also served as founding chairman of the board and CEO of our predecessor company, CytomX, LLC, from 2006 to 2008. Mr. Gluck has served as a member of the board of Cynvenio Biosystems, Inc. (now LungLife AI), a private company that was spun off from CytomX in 2008, since 2008. He also served as co-chairman of the board of TrueVision Systems Inc. (“TrueVision”), a private company where he has served on the board from 2007 until 2018, when it was sold to Alcon. Mr. Gluck served as a consultant to McKinsey & Company, Inc., an international management-consulting firm (“McKinsey”), from July 1998 to July 2003. Prior to that, he was Vice Chairman and Director of Bechtel Group, Inc., an engineering, construction and project management company, from 1995 to July 1998. Mr. Gluck is a former partner of McKinsey, where he served from 1967 to 1995. Between 1988 and 1994, he led McKinsey as its global Managing Director. He also serves as a director of the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus). Mr. Gluck has also served as the presiding director of the Hospital Corporation of America. Mr. Gluck received his B.S. from Manhattan College and M.S. from New York University in electrical engineering. We believe that Mr. Gluck is qualified to serve on our Board due to his extensive management experience, substantial experience in the life sciences industry and his well-known expertise in corporate strategy.

Basic Compensation

Total Annual Compensation, USD 49,375
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 87,122
Fiscal Year Total, USD 136,497

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy

3,769,930

Carlos Campoy

--

Amy Peterson

3,395,720

W. Michael Kavanaugh

1,477,000

Lloyd Rowland

1,097,840

Nick Galli

--
As Of  31 Dec 2019